Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3803424 | 0.94 | MAPT (0.52) | MAPTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3797616 | 0.93 | MAPT (0.51) | MAPTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3801913 | 0.89 | MAPT (0.45) | MAPTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3799752 | 0.88 | MAPT (0.47) | MAPTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3802368 | 0.88 | MAPT (0.44) | MAPTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL5150469 | 0.88 | MAPT (0.75) | MAPTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3797304 | 0.87 | MAPT (0.50) | MAPTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL14276298 | 0.87 | MAPT (0.64) | MAPTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL4869419 | 0.86 | MAPT (0.60) | MAPTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL3802544 | 0.86 | MAPT (0.44) | MAPTPOLBKDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714137-B2 | 2,2-Dichloro-N-[2-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-(4-pyridyl)]Acetamide; Hepatitis C virus | RIGEL PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080171871-A1 | Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-7332602-B2 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332602-B2 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070155966-A1 | Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection | RIGEL PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155966-A1 | Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection | RIGEL PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7157473-B2 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | RIGEL PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040127497-A1 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | MIDCAP FINANCIAL TRUST | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127497-A1 | Pyridyl substituted heterocycles useful for treating or preventing HCV infection | HAVCR2, HCCS, NQO1 | MAPT 4676/4885POLB 499/4885KDM4E 2996/4885 |
| US-20070155966-A1 | Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection | HAVCR2, HCCS, NQO1 | MAPT 4671/4885POLB 397/4885KDM4E 3087/4885 |
| US-20080171871-A1 | Pyridyl Substituted Heterocycles Useful For Treating Or Preventing HCV Infection | HAVCR2, HCCS, NQO1 | MAPT 4676/4885POLB 499/4885KDM4E 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.